Tin tức & Cập nhật

For men with erectile dysfunction (ED) who show a lack of response to oral phosphodiesterase type 5 inhibitors (PDE5Is), combination therapy with topical alprostadil plus PDE5Is seems favourable, producing greater improvements in sexual function without compromising safety compared with topical alprostadil alone, as shown in a study.

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.

The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.

ß3-adrenergic receptor agonists (ß3 agonists), such as mirabegron, demonstrate effectiveness and a satisfactory safety profile as adjunctive therapy in the management of paediatric neurogenic detrusor overactivity (NDO) or overactive bladder, results of a study have shown.

In men with erectile dysfunction (ED), adjuvant daily oral therapy with L-arginine and tadalafil was effective and safe in enhancing the efficacy and duration of benefits of low-intensity extracorporeal shockwave therapy (Li-ESWT), a study has shown.

Patients with prostate cancer (PCa) have lower levels of melatonin than those without PCa, independent of urinary symptomatology or extension and aggressiveness of the tumour, a study has found.

In patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression while on enzalutamide treatment, continuing enzalutamide appears to improve progression-free survival (PFS), according to results of the phase IIIb PRESIDE trial.